| Name | N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide |
|---|---|
| Synonyms |
isocarboxazide
Benazide 5-Methyl-isoxazol-3-carbonsaeure-(N'-benzyl-hydrazid) Marplan Isocarboxazidum N'-Benzyl-5-methylisoxazol-3-carbohydrazid Isocarboxazida 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide N'-benzyl-5-méthylisoxazole-3-carbohydrazide Isocarbonazid Isocarboxazid N'-benzyl-5-methylisoxazole-3-carbohydrazide N-Benzyl-N'-<5-methyl-isoxazol-3-yl>-carbonyl-hydrazin Isocarbossazide N'-Benzyl-5-methyl-1,2-oxazole-3-carbohydrazide Isocarboxyzid Enerzer 5-methyl-isoxazole-3-carboxylic acid-(N'-benzyl-hydrazide) isocarboxacid 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide |
| Description | Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 4.8 μM (rat brain monoamine oxidase)[1]. |
| In Vivo | Isocarboxazid (1, 3 mg/kg, i.p., 60 min) pretreatment in mice shows the significant increased number of head twitches at 15 and 30 min after 5-HTP[2]. Isocarboxazid (1, 3 mg/kg, i.p., 60 min) treatment in mice together with 5-HTP administration causes 43% 5-HT concentration increased and 22% of 5-HIAA decreased compared to brain concentrations in mice given 5-HTP alone[2]. Animal Model: Twelve male mice of dd strain (20-25 g)[2] Dosage: 0, 0.3,1, 3 mg/kg Administration: Intraperitoneally 60 min before intravenous injection of 5-HTP Result: The number of head twitches at 15 and 30 min after 5-HTP was increased. 43% 5-HT concentration increased and 22% of 5-HIAA decreased. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 394.5±42.0 °C at 760 mmHg |
| Melting Point | 98-100ºC |
| Molecular Formula | C12H13N3O2 |
| Molecular Weight | 231.251 |
| Flash Point | 192.4±27.9 °C |
| Exact Mass | 231.100784 |
| PSA | 67.16000 |
| LogP | 1.03 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
| Index of Refraction | 1.573 |
| Storage condition | -20°C Freezer |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | Missing Phrase - N15.00950417 |
| RIDADR | UN 3249 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
| HS Code | 2934999090 |
|
~%
59-63-2 |
| Literature: Journal of Heterocyclic Chemistry, , vol. 46, # 5 p. 909 - 913 |
|
~%
59-63-2 |
| Literature: Journal of Medicinal and Pharmaceutical Chemistry, , vol. 2, p. 133 - 145 |
|
~%
59-63-2 |
| Literature: Journal of Medicinal and Pharmaceutical Chemistry, , vol. 2, p. 133 - 145 |
|
~%
59-63-2 |
| Literature: Journal of Medicinal and Pharmaceutical Chemistry, , vol. 2, p. 133 - 145 |
|
~%
59-63-2 |
| Literature: Journal of Medicinal and Pharmaceutical Chemistry, , vol. 2, p. 133 - 145 US2908688 , ; |
| Precursor 6 | |
|---|---|
| DownStream 1 | |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |